Avineuro Completed Phase II Clinical Study Of AVN-211, A Selective 5-HT6 Receptor Antagonist

Avineuro LLC announced completion of phase II pilot clinical study of AVN-211, a proprietary orally-bioavailable molecule of a 5-HT6 receptor antagonist. In a multicenter double-blind randomized placebo-controlled pilot study of efficacy and safety of AVN-211 for amplifying the effects of antipsychotic drugs in patients with schizophrenia in a condition of incomplete remission receiving stable...

Read More

AllaChem, LLC Сompletes Phase Ib/IIa Clinical Study with AV4025, an HCV NS5A Inhibitor

December 14, 2014. AllaChem, LLC, announced today a successful completion of phase Ib/IIa clinical study with AV4025, a proprietary orally-bioavailable small molecule that blocks HCV genome replication by targeting viral non-structural protein NS5A. In a double-blind, placebo-controlled, randomized study of safety, tolerability, pharmacokinetics and antiviral activity of AV-4025 in HCV-infected...

Read More

Alla Chem, LLC Announces Start of Phase Ib Proof-Of-Concept Clinical Study of AVR560, an HCV entry inhibitor, for the Treatment of Chronic Hepatitis C Infection

Hallandale Beach, Fl –May 15, 2014 — Alla Chem, LLC, announces today start of phase 1b clinical study of AVR560, an investigational, orally bioavailable HCV entry inhibitor, currently in clinical development for the treatment of chronic HCV infection. In this randomized, double-blind, placebo-controlled, multicentre study of safety, tolerability, pharmacokinetics and antiviral activity of AVR560...

Read More

Alla Chem, LLC Announces Initiation of Phase I Clinical Studies of ONC1-13B, a New Effective Anti-Androgen for the Treatment of Prostate Cancers

Hallandale Beach, Fl –May 14, 2014 — Alla Chem, LLC announces initiation of Phase 1 clinical study of ONC1-13B in patients with metastatic Castration Resistant Prostate Cancer (mCRPC). ONC1-13B is a next in-class small molecule anti-androgen for the treatment of Prostate Cancers. In preclinical studies, it was shown that ONC1-13B efficiently inhibits androgen receptor signaling pathway by...

Read More

Alla Chem, LLC Announces Start of Phase Ib Clinical Study of AV4025, an NS5A inhibitor, for the Treatment of Chronic Hepatitis C Infection

Hallandale Beach, Fl –May 12, 2014 — Alla Chem, LLC (Hallandale Beach, Fl), announces today start of phase 1b clinical study of AV4025, an investigational, orally bioavailable HCV NS5A inhibitor, currently in clinical development for the treatment of chronic HCV infection. In this randomized, double-blind, placebo-controlled, multicentre study of safety, tolerability, pharmacokinetics and...

Read More

AllaChem completes phase 1a clinical study with AV4025, an HCV NS5A inhibitor

October 7 , 2013. AllaChem, LLC, announced today a successful completion of phase 1a clinical study with AV4025, a proprietary orally-bioavailable small molecule that blocks HCV genome replication by targeting viral non-structural protein NS5A. In a double-blind, placebo-controlled, single ascending oral dose study of AV4025 safety and tolerability in healthy volunteers, each dose cohort (10...

Read More